How can gut health assist drug development? The surprising answer: far more than you might think. The gut microbiome, an ecosystem of trillions of microorganisms, not only regulates digestion but also profoundly influences how drugs are absorbed, metabolized, and tolerated. Think of the microbiome as a dynamic metabolic organ that influences a wide array of biochemical pathways.
Drug developers seek to understand and predict how drugs behave in the human body. For some treatments, such as cardiovascular drugs like digoxin and statins, or oncology drugs like irinotecan, this behavior is shaped not only by human physiology but also by the microbes in the gut that impact how well a drug works and is tolerated.
For example, certain gut bacteria, notably Eggerthella lenta strains, can chemically inactivate digoxin before absorption, reducing its efficacy and causing variable patient responses. Meanwhile, statin outcomes vary with microbiome profiles: some enhance cholesterol-lowering and metabolic benefits, while others blunt efficacy or heighten risks like dysglycaemia. Irinotecan’s severe gut toxicity stems from bacterial β-glucuronidases reactivating its detoxified metabolite in the colon, damaging the intestinal lining and limiting dosing.
Mapping the microbiome can open up new opportunities for optimizing treatments, detecting hidden risks, and improving clinical development. Does it all sound too good to be true? There is one significant issue hindering progress: the lack of standardized microbiome testing in drug development.
Developing standardized microbiome tests is difficult for several reasons:
● The gut is highly individualized. The composition of the microbiome is shaped by genetics, environment, diet, age, and lifestyle factors. This diversity means there is no single “healthy” baseline to compare against. For drug developers, the lack of a universal reference model complicates the creation of predictive tools that can be generalized across populations.
● No consensus on what to measure. Researchers and clinicians continue to debate which microbial species, community ratios, or metabolic end products most strongly influence drug efficacy and toxicity. Some drugs are altered by specific bacterial enzymes, while others are impacted by broader shifts in microbial diversity or metabolite production. The absence of clear, validated drug–microbiome biomarkers has slowed the development of practical diagnostic assays that pharmaceutical teams could use to select trial participants, customize dosing regimens, or predict side effects with confidence.
● Methods used are inconsistent. Across microbiome studies, methods vary at almost every stage, from sample collection (stool versus tissue), storage, DNA extraction, sequencing resolution (16S versus shotgun metagenomics), and bioinformatics pipelines. These differences generate high variability in results, making cross-study comparisons difficult, but not impossible. For regulators and drug developers, such inconsistency prevents datasets from reaching the level of reliability and reproducibility required for decision-making in clinical development.
● Translational gaps. Even when microbiome studies show associations with drug outcomes, the data are often not formatted or contextualized in a way that trial designers, clinicians, or pharmacologists can act upon. These gaps slow progress towards embedding microbiome insights in early R&D pipelines and in a real-world setting, keeping pharmacomicrobiomics at the discovery level rather than routine clinical use.
● Lack of causal evidence (until recently). Historically, most microbiome research has highlighted correlations, such as links between microbial composition and patient drug response, without providing robust, causal evidence that could reliably guide therapeutic decision-making. Only in recent years, with advances in longitudinal studies, next-generation sequencing, functional assays, and AI modelling, has actionable microbiome-drug interaction data emerged (1,2,3).
Breakthroughs in microbiome science are now starting to emerge. For example, testing has evolved far beyond counting total microbial load or abundance. Next-generation sequencing and AI-driven algorithms can deliver in-depth maps of an individual microbial ecosystem, exposing dysbiosis, functional diversity, and microbial “signatures” that influence how patients metabolise specific therapies. These insights can be fed back into drug pipelines, enabling patient stratification, selecting trial cohorts less likely to experience adverse effects, and tailoring treatment pathways.
Recent evidence now shows that weaving microbiome insights into early R&D through to clinical trials can boost safety, efficacy, and ultimately patient outcomes (4). We now know that gut microbes influence drugs in two main ways: directly, by chemically transforming compounds via microbial enzymes; and indirectly, by reshaping host metabolism, immune pathways, and microbial communities that dictate absorption and response (5).
The study of drug-microbiome interactions (pharmacomicrobiomics), is an emerging field. Optimising existing pharmaceutical therapies like statins and gut microbial composition can help predict who will likely benefit and who may be at greater risk of adverse reactions. This is because a person’s microbiome influences both drug effectiveness and side effects. By profiling individual microbiomes, testing can pinpoint patient-specific differences, enabling smarter decisions about drug selection and dosing. To support this, researchers are using in-silico models, microbial stability assays, gut fermentation systems, and animal studies to identify microbiome-related risks before therapies enter clinical trials. Additionally, machine learning and high-resolution microbiome profiling are accelerating the discovery of beneficial strains for use as probiotics or live biotherapeutics.
However, hurdles remain, from patchy drug–microbiome data and ecological complexity to the lack of standardised methods. Still, regulatory frameworks are evolving, and recently FDA approved two microbiome-based therapies as standard treatment for a specific condition/rCDI.
The integration of microbiome science and drug testing is opening a new frontier in drug development. On one hand, it offers the potential to improve existing therapies by tailoring dose and response based on how the gut microbiome influences drug metabolism, thereby boosting efficacy and reducing side effects. On the other hand, it is driving the creation of novel therapeutics and personalized treatments derived directly from insights into gut health. By embracing this new frontier, we can unlock a future where medicines are not only more effective but also precisely tailored to each individual's unique biological makeup.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
References
- A Metwaly et al., "A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research," Nat Rev Gastroenterol Hepatol., 22, 343–356 (2025). DOI: 10.1038/s41575-025-01041-3.
- ID Wilson and JK Nicholson, "Gut Microbiome Interactions with Drug Metabolism, Efficacy and Toxicity," Transl Res., 179, 204–222 (2016). DOI: 10.1016/j.trsl.2016.08.002.
- A Belančić et al., "Microbiome-driven PKs: redefining drug metabolism beyond host enzymes," Expert Opin Drug Metab Toxicol., 22, 9–28 (2026). DOI: 10.1080/17425255.2026.2631415.
- SN Chaudhari et al., "Chains of evidence from correlations to causal molecules in microbiome-linked diseases," Nat Chem Biol., 17, 1046–1056 (2021). DOI: 10.1038/s41589-021-00861-z.
- S Al-Btoosh, RF Donnelly, and SA Kelly, "Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome," Gut Microbes, 18(1), 2604867 (2025). DOI: 10.1080/19490976.2025.2604867.
